Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31

In patients with HER2-positive metastatic breast cancer, lapatinib with taxane was associated with shorter ITT PFS and more toxicity vs. trastuzumab with taxane (median PFS was 9.1 months with lapatinib and 13.6 months with trastuzumab (HR, 1.48; 95% CI, 1.20 to 1.83; P < 0.001).

In 2012, NICE was informed by the manufacturer of lapatinib, that it had withdrawn its application for a centralised marketing authorisation for lapatinib in combination with paclitaxel.

 

 

Lapatinib is currently not licensed for use with taxanes for the treatment of adult patients with breast cancer, whose tumours overexpress HER2